$PHBI on alert, news out last week: CARSON CITY, NV, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to announce today that the company executed all the required documents for an Equity Purchase Agreement (the "Equity Agreement"
with Oscaleta Partners LLC ("Oscaleta", as stated earlier in the news release dated November 12, 2019, that should enable Pharmagreen to access capital over the next 2 years to support its current growth plans. The terms of the Equity Agreement will give Pharmagreen the right, but never the obligation, to sell to Oscaleta up to Ten Million Dollars’ worth of Pharmagreen’s registered common stock over an anticipated two-year period at times and in amounts that Pharmagreen deems appropriate. #stocks
Now that the Equity Agreement is fully executed, the company has started immediate work on the registration statement. The company plans to access the capital for its ongoing project development for state of the art greenhouse and tissue cultured starter plantlets production facility construction. Pharmagreen’s primary use of the facilities is to supply hemp farmers with its “CBD Dana” hemp strain that is a very high yielder of high CBD content biomass and flower tops, please visit our website; www.pharmagreen.ca
Peter Wojcik, President and CEO, stated, “Partnering with Oscaleta is significant for the company as we can be concerting on executing our business plan and growing the company, while Oscaleta funding agreements with their years of expertise and established network in the industry provides us with additional support in the financial market.”
Commenting on the investment, Stephen Hicks, Manager of Oscaleta, said, "As an institutional investor for more than 20 years, we partner with companies that meet very specific criteria – it boils down to 'how revolutionary is this?' We're excited about the long-term potential."
with Oscaleta Partners LLC ("Oscaleta", as stated earlier in the news release dated November 12, 2019, that should enable Pharmagreen to access capital over the next 2 years to support its current growth plans. The terms of the Equity Agreement will give Pharmagreen the right, but never the obligation, to sell to Oscaleta up to Ten Million Dollars’ worth of Pharmagreen’s registered common stock over an anticipated two-year period at times and in amounts that Pharmagreen deems appropriate. #stocks Now that the Equity Agreement is fully executed, the company has started immediate work on the registration statement. The company plans to access the capital for its ongoing project development for state of the art greenhouse and tissue cultured starter plantlets production facility construction. Pharmagreen’s primary use of the facilities is to supply hemp farmers with its “CBD Dana” hemp strain that is a very high yielder of high CBD content biomass and flower tops, please visit our website; www.pharmagreen.ca
Peter Wojcik, President and CEO, stated, “Partnering with Oscaleta is significant for the company as we can be concerting on executing our business plan and growing the company, while Oscaleta funding agreements with their years of expertise and established network in the industry provides us with additional support in the financial market.”
Commenting on the investment, Stephen Hicks, Manager of Oscaleta, said, "As an institutional investor for more than 20 years, we partner with companies that meet very specific criteria – it boils down to 'how revolutionary is this?' We're excited about the long-term potential."
